PA8601901A1 - Pirazoles como inhibidores de factor de necrosis tumoral - Google Patents

Pirazoles como inhibidores de factor de necrosis tumoral

Info

Publication number
PA8601901A1
PA8601901A1 PA20048601901A PA8601901A PA8601901A1 PA 8601901 A1 PA8601901 A1 PA 8601901A1 PA 20048601901 A PA20048601901 A PA 20048601901A PA 8601901 A PA8601901 A PA 8601901A PA 8601901 A1 PA8601901 A1 PA 8601901A1
Authority
PA
Panama
Prior art keywords
necrosis factor
tumor necrosis
pirazoles
factor inhibitors
compounds
Prior art date
Application number
PA20048601901A
Other languages
English (en)
Inventor
David R Borcherding
Alexandre Gross
Patrick Wai-Kwok Shum
Nicole Willard
Brian S Freed
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of PA8601901A1 publication Critical patent/PA8601901A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA COMPUESTOS DE LA FORMULA (I) Y PROFARMACOS ESTERICOS, SALES O SOLVATOS FARMACEUTICAMENTE ACEPTABLES DE COMPUESTOS DE ESE TIPO; O PROFARMACOS ESTERICOS DE SALES O SOLVATOS DE ESE TIPO; COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN COMPUESTOS DE ESE TIPO, SU PREPARACION Y SU USO FARMACEUTICO EN EL TRATAMIENTO DE ESTADOS DE ENFERMEDAD QUE PUEDEN MODULARSE MEDIANTE LA INHIBICION DE QUINASA P38 Y/O FACTOR DE NECROSIS TUMORAL (TNF).
PA20048601901A 2003-05-06 2004-05-06 Pirazoles como inhibidores de factor de necrosis tumoral PA8601901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46828503P 2003-05-06 2003-05-06

Publications (1)

Publication Number Publication Date
PA8601901A1 true PA8601901A1 (es) 2004-11-26

Family

ID=28792177

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048601901A PA8601901A1 (es) 2003-05-06 2004-05-06 Pirazoles como inhibidores de factor de necrosis tumoral

Country Status (26)

Country Link
US (1) US7541368B2 (es)
EP (1) EP1622610B1 (es)
JP (1) JP4714150B2 (es)
AT (1) ATE348610T1 (es)
AU (2) AU2004238241A1 (es)
BR (1) BRPI0409991A (es)
CA (1) CA2524043C (es)
CL (1) CL2004000965A1 (es)
CY (1) CY1107433T1 (es)
DE (1) DE602004003806T2 (es)
DK (1) DK1622610T3 (es)
ES (1) ES2277271T3 (es)
GB (1) GB0320244D0 (es)
HN (1) HN2004000150A (es)
HR (1) HRP20070020T3 (es)
JO (1) JO2473B1 (es)
MX (1) MXPA05011400A (es)
MY (1) MY140830A (es)
PA (1) PA8601901A1 (es)
PE (1) PE20050523A1 (es)
PL (1) PL1622610T3 (es)
PT (1) PT1622610E (es)
SI (1) SI1622610T1 (es)
TW (1) TWI335223B (es)
UY (1) UY28310A1 (es)
WO (1) WO2004100946A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
SI1761520T1 (sl) * 2004-06-23 2008-10-31 Lilly Co Eli Inhibitorji kinaze
GEP20104973B (en) 2004-08-12 2010-04-26 Pfizer Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
DE102004039789A1 (de) * 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101415685B (zh) 2006-01-31 2011-08-24 阿雷生物药品公司 激酶抑制剂及其使用方法
EP1987022A1 (en) * 2006-02-10 2008-11-05 Pfizer Products Inc. Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives
WO2007113005A2 (en) * 2006-04-03 2007-10-11 European Molecular Biology Laboratory (Embl) 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors
EP2051977A2 (en) * 2006-07-20 2009-04-29 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1
BRPI0719122A2 (pt) 2006-08-24 2013-12-10 Novartis Ag Compostos orgânicos
AU2007299870A1 (en) 2006-09-22 2008-03-27 Novartis Ag Heterocyclic organic compounds
CA2672776A1 (en) 2006-12-20 2008-06-26 Novartis Ag 2-substituted 5-membered heterocycles as scd inhibitors
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
NZ591427A (en) * 2008-10-02 2012-12-21 Respivert Ltd P38 map kinase inhibitors
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
WO2010067131A1 (en) * 2008-12-11 2010-06-17 Respivert Limited P38 map kinase inhibitors
EP2236505A1 (de) 2009-04-03 2010-10-06 Bayer CropScience AG Acylierte Aminopyridine und - pyridazine als Insektizide
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
WO2011021645A1 (ja) * 2009-08-19 2011-02-24 大日本住友製薬株式会社 2環性ウレア誘導体、またはその薬学的に許容される塩
WO2011066137A1 (en) 2009-11-24 2011-06-03 Schering Corporation Substituted biaryl derivatives and methods of use thereof
WO2011124930A1 (en) * 2010-04-08 2011-10-13 Respivert Limited P38 map kinase inhibitors
KR101332830B1 (ko) 2012-07-05 2013-11-27 한국화학연구원 페닐우레아 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 항암감작제
TWI648282B (zh) * 2014-03-27 2019-01-21 印度商托仁特生技有限公司 新熔合咪唑苯并噻唑化合物
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
WO2017152117A1 (en) 2016-03-03 2017-09-08 Cornell University Small molecule ire1-alpha inhibitors
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3142097A1 (en) 2018-05-30 2019-12-05 Washington University Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof
EP3883925A4 (en) * 2018-11-20 2021-12-29 Sironax Ltd Cyclic ureas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032110A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
US6316466B1 (en) * 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents

Also Published As

Publication number Publication date
US7541368B2 (en) 2009-06-02
DE602004003806D1 (de) 2007-02-01
ES2277271T3 (es) 2007-07-01
HRP20070020T3 (en) 2007-04-30
US20060063796A1 (en) 2006-03-23
JP4714150B2 (ja) 2011-06-29
GB0320244D0 (en) 2003-10-01
CL2004000965A1 (es) 2005-04-22
PL1622610T3 (pl) 2007-05-31
MY140830A (en) 2010-01-29
JO2473B1 (en) 2009-01-20
TW200509912A (en) 2005-03-16
BRPI0409991A (pt) 2006-05-09
EP1622610B1 (en) 2006-12-20
UY28310A1 (es) 2004-11-30
AU2010236021A1 (en) 2010-11-18
WO2004100946A1 (en) 2004-11-25
HN2004000150A (es) 2008-03-03
DE602004003806T2 (de) 2007-11-22
SI1622610T1 (sl) 2007-04-30
CY1107433T1 (el) 2012-12-19
DK1622610T3 (da) 2007-04-23
ATE348610T1 (de) 2007-01-15
PT1622610E (pt) 2007-02-28
PE20050523A1 (es) 2005-07-07
TWI335223B (en) 2011-01-01
AU2004238241A1 (en) 2004-11-25
MXPA05011400A (es) 2005-12-12
EP1622610A1 (en) 2006-02-08
JP2007502324A (ja) 2007-02-08
CA2524043A1 (en) 2004-11-25
CA2524043C (en) 2009-12-29

Similar Documents

Publication Publication Date Title
HN2004000150A (es) Pirazoles como inhibidores de factor de necrosis tumoral
IL260127B (en) mek inhibitors and methods of using them
EA200700902A1 (ru) 3-ариламинопиридиновые производные
ATE361300T1 (de) Derivate von heteroarylnitrilverbindungen
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
GB0112348D0 (en) Compounds
ATE353888T1 (de) Chinazolinderivate
IL180136A0 (en) 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
TW200612950A (en) Quinazolinedione derivatives as PARP inhibitors
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
MX2009005011A (es) Imidazopirazinas como inhibidores de proteina quinasa.
SE0402925D0 (sv) Novel Compounds
EA200501233A1 (ru) 4-аминопиримидин-5-он
DOP2004000898A (es) Pirazoles como inhibidores de factor de necrosis tumoral
EA201990219A3 (ru) Ингибиторы mek и способы их применения
UA96742C2 (en) Mek inhibitors and use thereof